RecruitingPhase 3NCT03165734
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Studying Primary myelofibrosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Swedish Orphan Biovitrum
- Principal Investigator
- Simran SinghSobi, Inc.
- Intervention
- Pacritinib(drug)
- Enrollment
- 399 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2017 – 2026
Study locations (20)
- University of Alabama at Birmingham, (UAB) Hospital, Comprehensive Cancer Center, Birmingham, Alabama, United States
- Mayo Clinic Hospital, Phoenix, Arizona, United States
- City of Hope, Duarte, California, United States
- USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
- UCLA David Geffen School of Medicine, Los Angeles, California, United States
- University of Colorado Cancer Center, Aurora, Colorado, United States
- Rocky Mountain Cancer Centers (US Oncology/McKesson), Boulder, Colorado, United States
- Yale School of Medicine, New Haven, Connecticut, United States
- Georgetown University Hospital, Washington D.C., District of Columbia, United States
- George Washington University-Medical Faculty Associates, Washington D.C., District of Columbia, United States
- Cleveland Clinic Florida, Weston, Florida, United States
- Northwestern Memorial Hospital, Chicago, Illinois, United States
- Rush University Medical Center, Chicago, Illinois, United States
- The University of Chicago Medical Center, Chicago, Illinois, United States
- University of Kansas Cancer Center and Medical Pavilion, Westwood, Kansas, United States
- +5 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03165734 on ClinicalTrials.govOther trials for Primary myelofibrosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07104799Momelotinib During and After HCT in MyelofibrosisMassachusetts General Hospital
- RECRUITINGPHASE3NCT07317700A Clinical Trial of Flonoltinib Maleate for Intermediate or High-Risk MyelofibrosisChengdu Zenitar Biomedical Technology Co., Ltd
- RECRUITINGPHASE1, PHASE2NCT07128381Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)M.D. Anderson Cancer Center
- RECRUITINGPHASE1, PHASE2NCT06887803A Study of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to JAK InhibitorsiOnctura
- RECRUITINGPHASE1, PHASE2NCT07281781Treating Anemia in Myelofibrosis With Repurposed Drugs (Nelfinavir) That Restore Iron Delivery to the Bone MarrowUniversity of California, Irvine
- ACTIVE NOT RECRUITINGNCT07342712Clinical Trail to Evaluate the Effect of Long-term Treatment With Gecacitinib on Myelofibrosis and Gene Mutation LevelsFirst Affiliated Hospital of Zhejiang University
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT06909136A Study to Evaluate Safety , Efficacy and Pharmacokinetics of WJ01024 Tablets Combined With Ruxolitinib in Patients With MyelofibrosisSuzhou Junjing BioSciences Co., Ltd.
- RECRUITINGPHASE2NCT06770842Ropeginterferon Alfa 2b Plus Ruxolitinib for MyelofibrosisThe University of Hong Kong